Effect of Daratumumab, Lenalidomide, and Dexamethasone on Quality of Life in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation.
10.19746/j.cnki.issn.1009-2137.2025.03.028
- Author:
Zhi-Hui LI
1
;
Jin-Hui WANG
1
;
Meng-Meng LIU
1
;
Peng-Tao XING
1
;
Yan-Ping ZHANG
1
;
Xin-Rong ZHAN
1
Author Information
1. Department 1 of Hematology, Xinxiang Central Hospital, Xinxiang 453003, Henan Province, China.
- Publication Type:Journal Article
- Keywords:
daratumumab;
lenalidomide;
dexamethasone;
multiple myeloma;
quality of life
- MeSH:
Humans;
Multiple Myeloma/drug therapy*;
Lenalidomide/therapeutic use*;
Quality of Life;
Dexamethasone/therapeutic use*;
Retrospective Studies;
Antibodies, Monoclonal/therapeutic use*;
Female;
Male;
Middle Aged;
Aged;
Stem Cell Transplantation
- From:
Journal of Experimental Hematology
2025;33(3):816-821
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of daratumumab, lenalidomide and dexamethasone on quality of life in transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM).
METHODS:The clinical data of 93 TIE NDMM patients in our hospital from January 2020 to December 2022 were retrospectively analyzed. The patients were divided into D-Rd group (48 cases) and Rd group (45 cases) according to treatment regimen. The patients in Rd group were treated with lenalidomide and dexamethasone, while those in D-Rd group were treated with daratumumab on the basis of Rd group. The QLQ-C30 and EQ-5D VAS scores of the two groups were compared at baseline and after 3, 6 and 12 treatment cycles. The last follow-up date was June 30, 2023, and overall survival (OS) was compared between the two groups.
RESULTS:The median follow-up period in the D-Rd group was 21 (7-38) months, and the median OS was 34 months, while that in the Rd group was 16 (5-35) months, and the median OS was 28 months. There was significant difference in OS between the two groups ( P <0.05). After 3, 6 and 12 treatment cycles, the QLQ-C30 score and EQ-5D VAS score of the two groups were significantly improved (all P <0.05). After 3 and 12 treatment cycles, the QLQ-C30 score and EQ-5D VAS score of D-Rd group were significantly higher than those of Rd group (all P <0.05). There were no significant differences in the improvement of QLQ-C30 GHS and pain scores between the two groups of patients with age <75 years and ECOG 0-1 score after 3, 6 and 12 treatment cycles (P >0.05). In D-Rd group of patients with age≥75 years, the improvement of QLQ-C30 GHS scores after 3 and 12 treatment cycles and QLQ-C30 pain scores after 3, 6 and 12 treatment cycles was significantly superior to that in Rd group (all P <0.05). In D-Rd group of patients with ECOG 2 scores, the improvement of QLQ-C30 GHS and pain scores after 3, 6 and 12 treatment cycles was significantly superior to that in Rd group (all P <0.05).
CONCLUSION:Daratumumab, lenalidomide, and dexamethasone can significantly improve OS in TIE NDMM patients without decrease of quality of life, especially in those with age≥75 years or ECOG 2 scores.
